These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 18270864)
1. Rituximab as a therapeutic tool in severe mixed cryoglobulinemia. Roccatello D; Baldovino S; Rossi D; Giachino O; Mansouri M; Naretto C; Di Simone D; Francica S; Cavallo R; Alpa M; Napoli F; Sena LM Clin Rev Allergy Immunol; 2008 Feb; 34(1):111-7. PubMed ID: 18270864 [TBL] [Abstract][Full Text] [Related]
2. Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Roccatello D; Baldovino S; Rossi D; Mansouri M; Naretto C; Gennaro M; Cavallo R; Alpa M; Costanzo P; Giachino O; Mazzucco G; Sena LM Nephrol Dial Transplant; 2004 Dec; 19(12):3054-61. PubMed ID: 15494358 [TBL] [Abstract][Full Text] [Related]
3. Rituximab in cryoglobulinemic peripheral neuropathy. Cavallo R; Roccatello D; Menegatti E; Naretto C; Napoli F; Baldovino S J Neurol; 2009 Jul; 256(7):1076-82. PubMed ID: 19263187 [TBL] [Abstract][Full Text] [Related]
4. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Ferri C; Cacoub P; Mazzaro C; Roccatello D; Scaini P; Sebastiani M; Tavoni A; Zignego AL; De Vita S Autoimmun Rev; 2011 Nov; 11(1):48-55. PubMed ID: 21821153 [TBL] [Abstract][Full Text] [Related]
5. Improvement in liver cirrhosis after treatment of HCV-related mixed cryoglobulinemia with rituximab. Petrarca A; Rigacci L; Monti M; Giannini C; Bernardi F; Caini P; Colagrande S; Bosi A; Laffi G; Zignego AL Dig Liver Dis; 2007 Sep; 39 Suppl 1():S129-33. PubMed ID: 17936214 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Zaja F; De Vita S; Mazzaro C; Sacco S; Damiani D; De Marchi G; Michelutti A; Baccarani M; Fanin R; Ferraccioli G Blood; 2003 May; 101(10):3827-34. PubMed ID: 12560225 [TBL] [Abstract][Full Text] [Related]
7. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C? Ahmed MS; Wong CF J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269 [TBL] [Abstract][Full Text] [Related]
8. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Saadoun D; Rosenzwajg M; Landau D; Piette JC; Klatzmann D; Cacoub P Blood; 2008 Jun; 111(11):5334-41. PubMed ID: 18292291 [TBL] [Abstract][Full Text] [Related]
9. Rituximab for the treatment of glomerulonephritis in hepatitis C associated cryoglobulinaemia. Korte MR; van Heerde MJ; de Man RA; Betjes MH Neth J Med; 2008 Jan; 66(1):27-30. PubMed ID: 18219065 [TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Basse G; Ribes D; Kamar N; Mehrenberger M; Esposito L; Guitard J; Lavayssière L; Oksman F; Durand D; Rostaing L Transplantation; 2005 Dec; 80(11):1560-4. PubMed ID: 16371926 [TBL] [Abstract][Full Text] [Related]
11. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Sansonno D; De Re V; Lauletta G; Tucci FA; Boiocchi M; Dammacco F Blood; 2003 May; 101(10):3818-26. PubMed ID: 12506023 [TBL] [Abstract][Full Text] [Related]
14. Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids. Quartuccio L; Soardo G; Romano G; Zaja F; Scott CA; De Marchi G; Fabris M; Ferraccioli G; De Vita S Rheumatology (Oxford); 2006 Jul; 45(7):842-6. PubMed ID: 16418196 [TBL] [Abstract][Full Text] [Related]
15. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Visentini M; Ludovisi S; Petrarca A; Pulvirenti F; Zaramella M; Monti M; Conti V; Ranieri J; Colantuono S; Fognani E; Piluso A; Tinelli C; Zignego AL; Mondelli MU; Fiorilli M; Casato M Autoimmun Rev; 2011 Sep; 10(11):714-9. PubMed ID: 21570494 [TBL] [Abstract][Full Text] [Related]
16. Improved (4 Plus 2) Rituximab Protocol for Severe Cases of Mixed Cryoglobulinemia: A 6-Year Observational Study. Roccatello D; Sciascia S; Baldovino S; Rossi D; Alpa M; Naretto C; Di Simone D; Menegatti E Am J Nephrol; 2016; 43(4):251-60. PubMed ID: 27161362 [TBL] [Abstract][Full Text] [Related]
17. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. De Vita S; Quartuccio L; Fabris M Dig Liver Dis; 2007 Sep; 39 Suppl 1():S122-8. PubMed ID: 17936213 [TBL] [Abstract][Full Text] [Related]
18. The etiology and pathophysiology of mixed cryoglobulinemia secondary to hepatitis C virus infection. Agnello V Springer Semin Immunopathol; 1997; 19(1):111-29. PubMed ID: 9266635 [TBL] [Abstract][Full Text] [Related]
19. Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease. Fabrizi F; Plaisier E; Saadoun D; Martin P; Messa P; Cacoub P Am J Kidney Dis; 2013 Apr; 61(4):623-37. PubMed ID: 23102733 [TBL] [Abstract][Full Text] [Related]